AI-generated summary
This comprehensive review integrates evidence on environmental, genetic, and epigenetic factors in myopia and pathologic myopia, along with precision medicine and therapies. The authors report that repeated low-level red-light therapy, low-dose atropine, and orthokeratology have shown promise in controlling myopia. They also note that gene-editing approaches are unlikely to become treatments in the near future.
- Who or what was studied
- unclear
- Limits stated in the abstract
- The abstract describes a narrative review and does not report the number of studies or participants included, nor a quantitative assessment of evidence strength.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on linkinghub.elsevier.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Myopia, Dose. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.